Introduction {#s1}
============

Poor diabetic tissue repair is a significant economic and social burden within the U.S., with monetary costs close to \$300 billion per annum; approximately 20% of that cost is spent specifically on diabetic ulcer care ([@B1],[@B2]). Despite improvements in diagnosis, outreach, and glucose management, multiple large clinical trials suggest that significant diabetic complications persist ([@B3]).

In particular, chronic hyperglycemia is implicated in the "metabolic memory" phenomenon that underlies diabetes-related complications including retinopathy, nephropathy, and poor wound healing ([@B4]). A common theme that has evolved from research into the cellular mechanisms behind diabetic complications is the mishandling of oxidative stress within diabetic tissues ([@B5]). Oxidative stress is characterized not only by an accumulation of reactive oxygen species (ROS) but also by an imbalance between ROS-producing pathways and the endogenous ROS-scavenging programs within cells.

The signaling pathway involving the transcription factor nuclear factor, erythroid 2-like 2 (Nrf2) and its key cytoplasmic repressor, Kelch-like ECH-associated protein 1 (Keap1), represents a central cellular defense mechanism to maintain redox homeostasis. Nrf2, a basic-region leucine zipper transcription factor, is an important regulator that translocates into the nucleus and activates a host of stress-response genes ([@B6]--[@B8]). Nrf2 regulates the basal and inducible expression of phase II detoxification enzymes and antioxidant stress proteins in response to endogenous and exogenous oxidative or electrophilic stresses ([@B9],[@B10]). Keap1, a Cul-E3 ligase, regulates Nrf2 turnover and the ability of Nrf2 to translocate into the nucleus and activate the cellular antioxidant response ([@B11]). Under "normal" physiologic conditions, Keap1, also an actin-binding cytoplasmic protein, interacts with Nrf2 and the cell's actin cytoskeleton to sequester Nrf2 in the cytoplasm and promote its ubiquitination and subsequent degradation by the 26S proteasome ([@B12],[@B13]). This "tethering" effect maintains basal gene expression of cytoprotective enzymes and proteins for redox homeostasis ([@B14]).

Several studies have indicated that the Keap1/Nrf2 pathway is altered in the context of chronic hyperglycemia, particularly in diabetic nephropathy ([@B15]). Secondary to the immediate response mechanisms by the mammalian body to protect against infection, wounds accumulate ROS. Under euglycemic conditions, cytoprotective mechanisms and pathways, such as the Keap1/Nrf2 axis, ensure the ROS do not overwhelm the healing tissues. Whether this pathway is dysfunctional in the context of nonhealing cutaneous wounds in chronic hyperglycemia is unknown. We hypothesize that Nrf2 dysfunction during diabetic cutaneous regeneration is a critical element contributing to diabetic wound pathology. As a corollary, we further hypothesize that *Keap1* inhibition will allow for a return to redox homeostasis, thus alleviating dysfunctional regeneration within this environment.

Research Design and Methods {#s2}
===========================

Fibroblast Cell Culture {#s3}
-----------------------

Our in vitro studies used murine NIH 3T3 fibroblasts (CRL-1658; American Type Culture Collection, Manassas, VA) in a model system of chronic hyperglycemic (HG) conditions using 25 mmol/L [d]{.smallcaps}-glucose DMEM (Life Technologies, Grand Island, NY) versus normoglycemic (NG) conditions using 5 mmol/L [d]{.smallcaps}-glucose DMEM (Life Technologies) based on previously published models of hyperglycemia ([@B16]). Media was supplemented with 10% FBS (Life Technologies) and 1% penicillin/streptomycin. Cells were cultured in 37°C at 5% CO~2~.

In Vitro Transfection {#s4}
---------------------

The role of Nrf2 signaling in 3T3 cells was investigated by inhibiting Keap1 using small interfering RNA (siRNA; siRNA mouse silencer select *Keap1* ID:s78526; Life Technologies). 3T3 fibroblasts at 70% confluence were plated in serum-starved conditions 6 h before transfection using 0.5% FBS in antibiotic-free media. siRNA--liposomal complexes were prepared per the manufacturer's instructions. Briefly, 2.5 nmol/L si*Keap1* or siScramble (AM4635; Life Technologies) were mixed with OptiMEM (Life Technologies). Separately, Lipofectamine 2000 (Life Technologies) was also mixed with OptiMEM. The siRNA and Lipofectamine dilutions were mixed at room temperature and incubated for 20 min. The siRNA--liposomal complexes were added to 3T3 cells and incubated for 24 h; 3 h following the addition of siRNA--liposomal complexes, the cell culture media was supplemented to 10% FBS. The media was changed 24 h later. For RNA and protein isolation, cells were collected 48 h after transfection.

Quantitative RT-PCR {#s5}
-------------------

Total RNA was harvested using the RNeasy Mini kit (Qiagen, Valencia, CA), according to the manufacturer's instructions, and 500 ng of total RNA was reverse transcribed using the High-Capacity cDNA Synthesis Kit (Applied Biosystems, Foster City, CA). mRNA quantification was determined by real-time quantitative RT-PCR using a SYBR Green detector (Life Technologies) and the ABI Prism 7900HT Sequence Detection System or QuantStudio 7 Flex (Applied Biosystems). Relative mRNA levels were calculated using a standard-curve method.

Preparation of Protein Lysates {#s6}
------------------------------

To generate protein lysates, transfected cells were trypsinized and harvested 48 h after transfection. Separate nuclear and cytoplasmic protein extracts were prepared as follows. Cells were lysed in a buffer of 10 mmol/L HEPES (pH 7.9), 10 mmol/L KCl, 0.1 mmol/L EDTA, 10 mmol/L dithiothreitol, 1× protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO), and 1× phosphatase inhibitor cocktail (Sigma-Aldrich). After vortexing for 15 s, the lysate was spun down at 15,000 rcf for 5 min for cells or 20 min for tissue to separate the cytoplasmic extract (supernatant) and nuclear extract (pellet). The cytoplasmic extract was removed into a prechilled tube and used directly or stored at −80°C. The nuclear extract pellet was resuspended in 20 mmol/L HEPES (pH 7.9), 0.4 mol/L NaCl, 1 mmol/L EDTA, 25% glycerol, 1× protease inhibitor cocktail, and 1× phosphatase inhibitor cocktail and incubated for 10 min. Nuclear lysate was separated by centrifugation at 15,000 rcf for 5 min for cells or 20 min for tissue and used immediately or stored at −80°C. Protein concentration was measured using Pierce 660 nm reagent (ThermoFisher) on a NanoDrop 2000 spectrophotometer (ThermoFisher).

Western Blotting and Immunoprecipitation {#s7}
----------------------------------------

Cytosolic or nuclear lysate (20 μg of either) was run on a 10% SDS-PAGE (Bio-Rad, Hercules, CA) and transferred to a polyvinylidene fluoride membrane (Bio-Rad). The membrane was blocked for 2 h using a solution of 5% milk in Tris-buffered saline with 0.1% Tween (Pierce, Rockford, IL) and probed with antibodies specific for Nrf2 (ab92946; Abcam, Cambridge, MA), Keap1 (60027--1-Ig; Proteintech, Chicago, IL), proliferating cell nuclear antigen (2586; Cell Signaling Technology, Danvers, MA), or β-actin (ab8229; Abcam). Immunoprecipitation of cytoplasmic lysates was performed using the Pierce Co-Immunoprecipitation Kit (26149; ThermoFisher), per the instructions, supplemented with protein A agarose beads (9863; Cell Signaling Technology). Secondary antibodies were species specific and conjugated in horseradish peroxidase (Cell Signaling Technology). Protein expression was detected on hyperfilm (Amersham Biosciences, Sunnyvale, CA) with ECL Plus reagent (ThermoFisher).

ROS Assay Using Chloromethyl-Dichlorodihydrofluorescein Diacetate {#s8}
-----------------------------------------------------------------

3T3 cells were trypsinized, centrifuged, and resuspended in 1× Hanks' balanced salt solution. Chloromethyl-dichlorodihydrofluorescein diacetate (CM-H~2~DCFDA) dissolved in DMSO was added to a final concentration of 5 µmol/L. Cells were incubated for 1 h in the dark at 37°C in 5% CO~2~. Incubation with 1 mmol/L diethyl malate was used as a positive control for high ROS. Following incubation, cells were placed on ice to temper further metabolism, and propidium iodide was added to a final concentration of 1 µg/mL. Live (propidium iodide--negative) cells were analyzed at 492- to 495-nm excitation and 517- to 527-nm emission on a FACSCalibur flow cytometry system (Becton Dickinson). Data were analyzed using FlowJo ([www.flowjo.com/](http://www.flowjo.com/)).

Measurement of 8-Hydroxy-2′-Deoxyguanosine {#s9}
------------------------------------------

ROS levels were determined by measuring the levels of 8-hydroxy-2′-deoxyguanosine (8-OHdG), a ROS-mediated DNA damage by-product, with an oxidative DNA damage ELISA kit (OxiSelect Oxidative DNA Damage ELISA; Cell Biolabs, San Diego, CA). ELISA was performed according to the manufacturer's instructions. Briefly, 100 μL of 8-OHdG--BSA conjugate in PBS was incubated overnight at 4°C in 96-well plates. After washing with distilled water, the plate was blocked with 200 μL of assay diluent for 1 h at room temperature. Samples and standards (50 μL) then were incubated for 10 min, followed by incubation for 1 h with 50 μL of anti--8-OHdG detection antibody. After washing, 100 μL of secondary antibody coupled with horseradish peroxidase was incubated for 1 h. After several washes, the peroxidase activity was detected by the addition of 100 μL of substrate solution and incubation for 5 min. The reaction was stopped with 100 μL of stop solution and measured at 450 nm on the Synergy H1 ELISA plate reader (BioTek, Winooski, VT). Data were standardized to total DNA concentration.

Animal Protocol {#s10}
---------------

All animal protocols were approved by the New York University Medical Center Animal Care Committee (International Animal Care and Use Committee protocol 061104-01). Male diabetic (Lepr^db/db^) mice (db/db) and nondiabetic mice C57BL/6J (wild type \[WT\], +/+), aged 12 weeks, were obtained from The Jackson Laboratory (Bar Harbor, ME). Glucometers were used to confirm hyperglycemic status. All db/db mice used in the experiments had blood glucose concentrations \>400 mg/dL on two random separate occasions. Mice were housed in a temperature-controlled, virus-free barrier animal facility with a 12-h light/12-h dark cycle and were maintained on chow diet/water ad libitum.

Preclinical Wounding Model {#s11}
--------------------------

An established murine model of excisional wound healing was used ([@B17]). The animals were anesthetized with inhalational 2% isoflurane. Hair on the dorsal skin was removed using a hair trimmer and Nair (Church & Dwight, Princeton, NJ). Paired 10-mm full-thickness wounds extending through the panniculus carnosus were created on the dorsum of the mice using a punch biopsy tool. The wounds then were splinted open with silicone stents fashioned from a 0.5-mm-thick silicone sheet (Grace Bio-Labs, Bend, OR). Stents were fixed to the skin using an immediate-bonding adhesive (Krazy Glue; Elmer's Products Inc., Columbus, OH), with the wound centered within the stent. This was followed by the placement of interrupted 5--0 nylon sutures (Ethicon, Inc., Somerville, NJ) to secure them in position. After the immediate-bonding adhesive dried, wounds were covered with an occlusive dressing (Tegaderm; 3M, St. Paul, MN). Standardized photographs were taken on days 1, 7, 14, 21, and 28 after wounding; they were digitally analyzed for the percent wound closure and calibrated against the internal diameter of the silicone stent to correct for magnification, perspective, or parallax effects. Time to wound closure (number of days for complete reepithelialization) and percent wound closure (1 − \[{wound area}/{original wound area}\]) were measured digitally (Adobe Systems, San Jose, CA). Area under the curve was calculated using the trapezoidal rule (GraphPad Prism software) to assess the regenerative potential of each wound.

Topical siRNA Treatment {#s12}
-----------------------

A 12-kDa U.S. Food and Drug Administration--approved 0.4% (weight for volume) agarose colloid matrix was created for the siRNA--liposomal transfection complex ([@B18]). Experimental arms included a treatment group, 200 pmol *Keap1* siRNA (*n* = 16), and a control group, 200 pmol scramble siRNA (*n* = 16). On the basis of prior experiments that outlined optimal dosing routines, *Keap1* siRNA and scramble siRNA were applied weekly (on days 1, 7, 14, and 21 after wounding). To assess the presence of siRNA in the skin we used siGLO Red (ThermoFisher) in the siRNA--liposomal complex and applied it to intact skin.

Animal Tissue Harvest {#s13}
---------------------

Eight animals from each group were killed on day 10. Wounds were collected for RNA, DNA, protein, and histological analyses. Tissue samples undergoing RNA extraction were placed in a Buffer RLT/β-mercaptoethanol solution (RNeasy Fibrous Tissue Kit; Qiagen) and homogenized using a polytron tissue homogenizer (Kinematica, Bohemia, NY). Tissues undergoing DNA extraction for 8-OHdG analysis were processed with a Buffer ALT/proteinase K solution according to the instructions of the DNeasy Blood & Tissue Kit (Qiagen). Following extractions, total RNA and DNA were quantified with a NanoDrop 2000 spectrophotometer (ThermoFisher). For siGLO Red--treated tissues, skin was fixed in 4% paraformaldehyde overnight and embedded in optimal cutting temperature medium.

In Vivo ROS Imaging {#s14}
-------------------

All mice were anesthetized with inhalational 2% isoflurane. L-012 (Wako Chemicals, Richmond, VA) was prepared in PBS at 0.5 mg/100 μL and injected intraperitoneally into mice (5 mg/200 g body weight). Bioluminescence was measured at 5-min intervals, and images were captured using the Spectrum in vivo imaging system (PerkinElmer, Waltham, MA).

Histology {#s15}
---------

On day 10 after wounding, wounds were excised and fixed in 10% formalin. The samples subsequently underwent routine histologic processing and were embedded in paraffin or optimal cutting temperature medium. Deparaffinized skin-tissue sections were stained with hematoxylin and eosin. The images were digitized to ×400 magnification using Nikon NIS Elements software (Nikon, Melville, NY) and subsequently analyzed for epithelial gap and granulation tissue formation using a previously established protocol ([@B17]). For epithelial gap measurements, four serial photographs taken on a Zeiss Axioskop 40 at ×5 magnification were superimposed using Adobe Photoshop to generate an image panning the complete width of the wound.

Immunofluorescence {#s16}
------------------

Paraffin tissue section slides were deparaffinized using subsequent washes in a gradient of xylenes, ethanol, and PBS. Antigens were retrieved using Tris--EDTA solution (1 mmol/L EDTA \[pH 8.0\], 10 mmol/L Tris \[pH 8.0\]) in a water bath microwaved for 6 min at 90% power. The tissue sections were blocked with PBS with 0.1% Tween-20 solution containing 2% BSA (Sigma-Aldrich) and 5% normal donkey serum (Jackson ImmunoResearch Laboratories). Additional blocking was performed using the Vector M.O.M. Immunodetection Kit (Vector Laboratories), according to the manufacturer's instructions. The tissue was probed using anti-Nrf2 antibody (sc-722; Santa Cruz Biotechnology) and anti-Keap1 antibody (sc-15246; Santa Cruz Biotechnology). Secondary antibodies (Alexa Fluor 488 AffiniPure donkey anti-mouse IgG, Alexa Fluor 594 AffiniPure donkey anti-rabbit IgG) were purchased from Jackson ImmunoResearch Laboratories and used at a dilution of 1:500 each.

Frozen skin-tissue sections were stained with rat anti-mouse CD31 primary antibody (BD Biosciences, Franklin Lakes, NJ) and goat anti-rat IgG secondary antibody (Alexa Fluor 594; Invitrogen). Slides were mounted with DAPI (Vector Laboratories) and viewed on a Nikon Eclipse Ni-U. DAPI was used to determine the sample outline, whereas immunofluorescent CD31 was used to identify vascular structures. Dual-filter images were superimposed to illustrate wound architecture and vascular staining (Photoshop; Adobe Systems Inc.). Vessels per high-powered field (hpf) also were counted. All experiments were performed in triplicate.

Total Glutathione Assay Methods {#s17}
-------------------------------

Cells were washed with ice-cold PBS twice before analysis with the GSH/GSSG-Glo kit (Promega, Madison, WI). Briefly, cells were lysed with total glutathione lysis reagent or oxidized glutathione lysis reagent, and the lysates were used within 10 min. Standards were prepared with the total glutathione reagent. The plates were shaken for 5 min. Luciferin generation reagent was added (50 μL/well), and after brief mixing by shaking the plate was incubated for 30 min at room temperature. Then, 100 μL luciferin detection reagent was added, mixed, and incubated for 15 min at room temperature. Luminescence was measured at room temperature with an integration time of 1 s/well. The linear portions of the standard curves were used to fit equations of lines, and the concentrations of unknown samples were calculated. The reduced glutathione (GSH)--to--glutathione disulfide (GSSG) ratio was calculated by adjusting for every mole of GSSG being derived from 1 mol of GSH. Samples were assayed in triplicate.

Statistical Analysis {#s18}
--------------------

All data are expressed as mean ± SD of at least three separate trials, each with *n* = 3. Student *t* tests and one-way ANOVA were applied to assess for statistical significance. A *P* value less than 0.05 determined statistical significance.

Results {#s19}
=======

Nrf2 Nuclear Translocation Is Dysfunctional in the Context of Chronic Hyperglycemia {#s20}
-----------------------------------------------------------------------------------

Our first goal was to determine the pattern of the Keap1/Nrf2 signaling pathway within diabetic cells. Using our in vitro model, we analyzed cytoplasmic protein lysates from NG- and HG-cultured 3T3 cells, and there were no striking differences in Nrf2 expression ([Fig. 1*A*](#F1){ref-type="fig"}). However, coimmunoprecipitation showed a relative increase in Keap1-bound Nrf2 in the cytosol of HG fibroblasts ([Fig. 1*B*](#F1){ref-type="fig"}). Hypothesizing that Keap1 was mediating defective Nrf2 translocation, we inhibited Keap1 using an siRNA-based strategy. We optimized a Lipofectamine-based method to inhibit *Keap1* gene expression to \<10% of baseline within 48 h of transfection in both NG and HG fibroblasts ([Fig. 1*C*](#F1){ref-type="fig"}). While NG conditions induce a basal level of Nrf2 nuclear translocation, little Nrf2 migrated to the nucleus in HG-cultured fibroblasts ([Fig. 1*D*](#F1){ref-type="fig"}). We observed maximal knockdown of Keap1 protein 2 days following transfection, resulting in a marked increase in the presence of nuclear Nrf2 in HG fibroblasts ([Fig. 1*D*](#F1){ref-type="fig"}). Using an in vitro model, our data showed evidence of altered Nrf2 protein expression within fibroblasts undergoing hyperglycemia-related oxidative stress.

![Defective Nrf2 nuclear translocation in chronic hyperglycemia can be alleviated by *Keap1* inhibition. Protein lysates of 3T3 fibroblasts cultured in either NG or chronic HG conditions were generated 48 h after introduction of si*Keap1* or control scramble siRNA. *A*: Cytoplasmic protein lysate (10 μg) from NG and chronic HG samples reveal relatively equivalent amounts of Nrf2 within the cytoplasm. *B*: Immunoprecipitation of cytosolic Keap1 demonstrates that there are notable differences between the proportions of Nrf2 sequestered by Keap1 in the cytoplasm between NG and HG 3T3s. *C*: Quantitative RT-PCR demonstrates that Lipofectamine-based si*Keap1* transfection effectively reduces *Keap1* expression in cultured fibroblasts to \<10% of baseline within 48 h compared with siScramble-transfected controls. *D*: Western blot of 3T3 fibroblast nuclear lysates from NG and chronic HG conditions demonstrates a nuclear signaling translocation defect that is restored 48 h after transfection with si*Keap1*. The same cytoplasmic lysate was used in *A* and *D*. \*\**P* \< 0.01. IP, immunoprecipitation with antibody against indicated protein; PCNA, proliferating cell nuclear antigen; WB, immunoblot with indicated antibody.](db150453f1){#F1}

Dysfunctional Nrf2 Signaling Creates Redox Imbalance That Can Be Rescued With *Keap1* Inhibition {#s21}
------------------------------------------------------------------------------------------------

We further investigated the downstream consequences of the Nrf2 translocation defect in chronic hyperglycemia. Using the same in vitro model, total RNA was isolated from fibroblasts, and gene expression was analyzed by quantitative RT-PCR. Expression of NAD(P)H dehydrogenase, quinone 1 (NQO1) and manganese superoxide dismutase (MnSOD), essential antioxidant genes controlling ROS within the cellular environment, was decreased in HG compared with their NG counterparts (72 ± 7.7% decrease and 38 ± 19.3% decrease, respectively; *P* \< 0.05) ([Fig. 2*A*](#F2){ref-type="fig"}). Following treatment with *Keap1* siRNA, the hyperglycemia-related reduction in antioxidant gene expression was rescued with 180% and 410% increases in gene expression of NQO1 and MnSOD, respectively (*P* \< 0.05) ([Fig. 2*B*](#F2){ref-type="fig"}). *Keap1* silencing significantly altered the gene expression of Nrf2 downstream targets heme oxygenase-1 (HO-1), glutathione reductase (GSR), glutathione peroxidase 1 (Gpx1), and glutathione-S-transferase µ1 (GSTµ1). With the exception of Gpx1, whose expression is downregulated to 84 ± 6%, gene expression of HO-1, GSR, and GSTµ1 increased to 162 ± 34%, 147 ± 12%, and 124 ± 14%, respectively ([Fig. 2*C*](#F2){ref-type="fig"}). Several growth factors associated with wound healing are also affected by *Keap1* silencing: nerve growth factor (NGF; 136 ± 15%), fibroblast growth factor (FGF) 1 (267 ± 190%), and FGF2 (117 ± 20%) ([Fig. 2*D*](#F2){ref-type="fig"}). Platelet-derived growth factor expression is not affected by si*Keap1*. We also evaluated the expression of inflammatory markers such as tumor necrosis factor (TNF)-α, monocyte chemoattractant protein 1 (MCP1), and interleukin (IL)-1β, but did not find any remarkable change ([Fig. 2*E*](#F2){ref-type="fig"}).

![*Keap1* inhibition improves ROS handling within fibroblasts by enhancing activation of the endogenous antioxidant program. Gene expression and ROS handling were assessed in vitro following *Keap1* silencing. *A*: Chronic hyperglycemia impairs activation of NQO1 and MnSOD by 72% and 38%, respectively, compared with NG controls. *B*: siRNA-mediated reduction of *Keap1* expression rescues MnSOD and NQO1 expression to 180% and 410% of controls, respectively. *C--E*: Gene expression analysis of Nrf2 target genes (*C*), growth factors (*D*), and inflammatory markers (*E*) with and without *Keap1* silencing. *F*: Assessment of GSH/GSSG content with si*Keap1*. *G*: CM-H~2~DCFDA--based fluorescent assessment of ROS production reveals that real-time ROS production in HG fibroblasts can be reduced to that of NG cells with si*Keap1*. *H*: *Keap1* inhibition within HG fibroblasts reduces the ROS by-product 8-OHdG by 62% compared with control. 8-OHdG in NG cells is nonsignificantly decreased by 25%. *I*: db/db Mice have 5.6-fold greater accumulation of ROS in wounded skin compared with WT controls; intact db/db skin accumulates 3.5-fold more ROS than wounded WT skin. \**P* \< 0.05, \*\**P* \< 0.01. DEM, diethyl malate; ns, not significant; PDGF, platelet-derived growth factor; siNS, nonsense siRNA.](db150453f2){#F2}

To correlate these changes in gene expression with the cellular redox state, we characterized the oxidative state of fibroblasts using several measures. Because glutathione is abundant in cells and the ratio of GSH to GSSG is considered an indicator of redox environment, we assayed total glutathione following si*Keap1* treatment. We found the GSH-to-GSSG ratio increased to 24.77 ± 3.089 in si*Keap1*-treated fibroblasts in comparison with 7.85 ± 0.98 in scramble-treated ones, indicating a decrease in the oxidized GSSG form and a corresponding increase in the GSH form ([Fig. 2*F*](#F2){ref-type="fig"}). To investigate ROS stress, fibroblasts were incubated with the intracellular ROS indicator CM-H~2~DCFDA. Using flow cytometry to assess the level of fluorescence of the ROS-induced adduct, we found that *Keap1*-silenced HG fibroblasts demonstrated significantly reduced intracellular oxidative status, consistent with an enhanced ROS-scavenging potential, compared with NG and HG scramble controls ([Fig. 2*G*](#F2){ref-type="fig"}). Similarly, an ELISA-based determination of 8-OHdG levels allowed assessment of longer-term ROS accumulation. We found that HG fibroblasts demonstrated an increased baseline value that is 290% of NG 8-OHdG ([Fig. 2*H*](#F2){ref-type="fig"}). However, silencing *Keap1* reduced 8-OHdG in HG fibroblasts by 62% ([Fig. 2*H*](#F2){ref-type="fig"}). Inhibition of *Keap1* in NG fibroblasts reduced 8-OHdG accumulation by only 25% compared with the NG control ([Fig. 2*H*](#F2){ref-type="fig"}). 8-OHdG quantification and comparison between uninjured db/db skin and WT skin demonstrated that diabetic skin accumulates 25-fold more 8-OHdG ([Fig. 2*I*](#F2){ref-type="fig"}). Tissue samples from the wound bed also demonstrated sixfold more 8-OHdG within db/db samples compared with WT samples ([Fig. 2*I*](#F2){ref-type="fig"}).

Topical si*Keap1* Therapy Improves the Redox Profile in Diabetic Mice and Accelerates Their Regenerative Capacity {#s22}
-----------------------------------------------------------------------------------------------------------------

To transition to an in vivo assessment of Nrf2 signaling on redox homeostasis and regeneration, we used a validated stented-wound model of diabetic wound healing ([Fig. 3*A*](#F3){ref-type="fig"}). We adapted our in vitro use of *Keap1* siRNA to an in vivo preclinical therapy by topical weekly application of 200 pmol siRNA suspended in an agarose matrix to 10-mm diameter wounds weekly ([Fig. 3*A*](#F3){ref-type="fig"}). Quantitative RT-PCR analysis of mRNA extracted from wounds 10 days into healing demonstrated that si*Keap1* therapy reduced *Keap1* expression within diabetic wounds by 36% ([Fig. 3*B*](#F3){ref-type="fig"}). Expression of antioxidant gene NQO1 increased by 73% in diabetic wounds treated with si*Keap1* compared with control therapy at 10 days ([Fig. 3*C*](#F3){ref-type="fig"}). Expression of MnSOD, however, was not significantly altered following si*Keap1* therapy in vivo ([Fig. 3*D*](#F3){ref-type="fig"}). Following *Keap1* silencing in the wound bed, Nrf2 target gene HO-1 expression increased by 179 ± 30%, GSR by 133 ± 23%, and GSTµ1 by 172 ± 32% ([Fig. 3*E*](#F3){ref-type="fig"}). Growth factors NGF and FGF1 also increased with silenced *Keap1* to 174 ± 35% and 157 ± 73%, respectively ([Fig. 3*F*](#F3){ref-type="fig"}). FGF2 expression significantly decreased in the wound bed with si*Keap1* therapy ([Fig. 3*F*](#F3){ref-type="fig"}). In contrast to in vitro *Keap1* silencing, inflammatory markers TNF-α, MCP1, and IL-1β were all significantly affected with *Keap1* inhibition in vivo. TNF-α expression increased by 788 ± 193% and IL-1β expression increased by 680 ± 77% ([Fig. 3*G*](#F3){ref-type="fig"}). MCP1 expression decreased to 24 ± 12% of that in scramble-treated diabetic wounds ([Fig. 3*G*](#F3){ref-type="fig"}).

![*Keap1* silencing in vivo upregulates Nrf2-mediated antioxidant mechanisms. Wound healing in db/db mice was analyzed using a validated stented-wound model, and the effect of weekly topical si*Keap1* therapy was evaluated on macroscopic and molecular levels. *A*: Schematic of topical si*Keap1* therapy. *B*: mRNA from si*Keap1*-treated wounds shows a 36% reduction in *Keap1* expression 10 days into treatment. *C*: Ten days into treatment, topical si*Keap1* therapy increases NQO1 expression in wounds by 73% compared with scramble siRNA. *D*: MnSOD expression in 10-day treated diabetic wounds. *E--G*: Gene expression of Nrf2 target genes (*E*), growth factors (*F*), and inflammatory factors (*G*) in wound beds following si*Keap1* topical therapy. *H--M*: Immunofluorescence of Nrf2 and Keap1 in tissue sections of wounded diabetic tissue, with indicated topical siRNA therapy. All images are ×10 magnification. Insets in *J* and *M* are ×20 magnification. Open arrowheads show low expression in the indicated region; white arrows show upregulated expression in the indicated region; asterisks note autofluorescence. The dotted line demarcates the epidermis (above) and dermis (below) at the wound edge. PDGF, platelet-derived growth factor; siNS, nonsense siRNA. \**P* \< 0.05. \*\**P* \< 0.01.](db150453f3){#F3}

Next we investigated the effect of *Keap1* therapy on Nrf2 and Keap1 protein expression in skin-tissue sections of 10-day wounds harvested from db/db mice. In the absence of si*Keap1* there is lack of Nrf2 expression in the wound bed and bordering skin ([Fig. 3*H* and *J*](#F3){ref-type="fig"}). Upon application of si*Keap1*, Nrf2 expression was upregulated in epidermis, dermis, and wound granulation tissue at the wound edge ([Fig. 3*K* and *M*](#F3){ref-type="fig"}). Specifically, more nuclear expression of Nrf2 is obvious in the granulation tissue of wounds that received topical si*Keap1* ([Fig. 3*M*](#F3){ref-type="fig"}, inset). In a corresponding manner, Keap1 immunoreactivity in epidermis and dermis decreased following silencing ([Fig. 3*I*, *L*, and *M*](#F3){ref-type="fig"}). Our results demonstrate that topical si*Keap1* is sufficient to upregulate Nrf2 expression and its downstream effects.

The clinical relevance of this altered metabolic state is demonstrated in [Fig. 4](#F4){ref-type="fig"}. The full-thickness wounds on the dorsal skin of db/db mice that were treated with scramble or si*Keap1* were monitored until the wound healed completely. Topical si*Keap1* therapy reduced time to wound closure to 21 days, compared with the 30 days required by scramble-treated wounds ([Fig. 4*A*](#F4){ref-type="fig"}). The wound closure rates between diabetic and WT mice are noticeably different as early as 7 days after excision (52% vs. 18% closure; *P* \< 0.05) ([Fig. 4*B*](#F4){ref-type="fig"}). Topical siRNA therapy targeted against *Keap1* accelerated wound closure in db/db mice when compared with scramble siRNA--treated wounds (*P* \< 0.01 at all time points observed), closely mimicking the WT closure pattern ([Fig. 4*B*](#F4){ref-type="fig"}). Area under the curve analysis revealed that si*Keap1* treatment corrected the regenerative delay and wound burden by 49% ([Fig. 4*C*](#F4){ref-type="fig"}).

![Topical si*Keap1* gene therapy accelerates diabetic wound closure. *A*: Photographs of stented wounds demonstrating accelerated wound closure with weekly topical si*Keap1* therapy. *B*: Topical si*Keap1* therapy accelerates diabetic wound closure by 7 days compared with nontreated controls. *C*: Wound burden analysis demonstrates that topical si*Keap1* therapy enhances diabetic wound healing by 49% compared with scramble control. *D*: Dermal penetration and accumulation of siRNA in cryosections of diabetic mouse skin treated with siGLO Red--liposomal complex. At 10 days after application, siGLO Red is present up to the panniculus carnosus. Scale bar, 100 μm. Inset is magnification of area in dashed box. *E*: In vivo imaging system imaging of 7-day-old wounds using systemically delivered L-012 reagent demonstrates that topical si*Keap1* treatment reduces real-time ROS accumulation compared with control diabetic wounds. *F*: Quantification of L-012 bioluminescence demonstrating a 58% decrease in ROS levels within diabetic wounds treated with topical si*Keap1* therapy. *G*: The downstream ROS by-product 8-OHdG is also reduced by 42% with topical si*Keap1* therapy compared with scramble-treated wounds. d, day. \**P* \< 0.05. \*\**P* \< 0.01.](db150453f4){#F4}

We next examined the extent of penetration of the topical siRNA therapy in the mouse skin using a fluorophore-tagged siRNA, siGLO Red, in the siRNA--liposomal complex. We found accumulated siGLO Red in the skin down to the panniculus carnosus ([Fig. 4*D*](#F4){ref-type="fig"}). To investigate whether the accumulation of si*Keap1* in mouse skin, changes in redox gene expression, and accelerated wound closure correspond with ROS handling, we assessed real-time in vivo ROS concentrations within diabetic wounds by measuring L-012 bioluminescence. Seven days after topical si*Keap1* application, diabetic wounds demonstrated improved redox homeostasis ([Fig. 4*E*](#F4){ref-type="fig"}). Compared with scramble siRNA--treated wounds showing 45,775 ± 11,649 ROS bioluminescence units/cm^2^, siKeap1-treated wounds showed a remarkable 58% decrease to 19,405 ± 5,939 ROS bioluminescence units/cm^2^ (*P* = 0.04; [Fig. 4*F*](#F4){ref-type="fig"}). Similarly, 8-OHdG ELISA analysis revealed that topical si*Keap1* therapy reduced downstream by-products of ROS accumulation by 42%: from 13.16 ± 2.4 ng/mL in scramble control wounds to 7.64 ± 1 ng/mL in siKeap1 wounds (*P* \< 0.05; [Fig. 4*G*](#F4){ref-type="fig"}).

When correlating other measures of regeneration, we observed that topical si*Keap1* treatment advantageously altered the histologic wound profile. The epithelial gap, or the distance between the healing edges of a wound, significantly decreased from 11,561 ± 1,175 μm in siScramble-treated wounds to 4,728 ± 302.4 µm in si*Keap1*-treated ones ([Fig. 5*A* and *B*](#F5){ref-type="fig"}). Supporting this observation, a significant increase in wound granulation tissue was appreciated with topical si*Keap1* treatment (197,148 µm^2^ in si*Keap1*-treated wounds vs. 53,165 µm^2^ in controls; *P* \< 0.0001; [Fig. 5*C* and *D*](#F5){ref-type="fig"}). Immunofluorescent staining showed that *Keap1* inhibition increased the area of expression of CD31, a marker of neovascularization ([Fig. 5*E*](#F5){ref-type="fig"}). We found 61 CD31+ cells/hpf in si*Keap1*-treated wounds versus 18 CD31+ cells/hpf in controls (*P* = 0.0016; [Fig. 5*F*](#F5){ref-type="fig"}). Our data strongly suggest that silencing *Keap1* in diabetic cutaneous wounds improves their redox status and promotes the generation of features necessary for successful neovascularization and reepithelialization.

![Topical si*Keap1* gene therapy improves the histologic profile of diabetic wounds. Ten-day-old diabetic wounds were analyzed histologically to study the effect of topical si*Keap1* therapy on reepithelialization and neovascularization. *A*: Hematoxylin and eosin--stained sections demonstrate accelerated reepithelialization in si*Keap1*-treated wounds. The yellow dotted lines indicate wound boundaries. *B*: Quantification of the epithelial gap. *C*: si*Keap1*-treated diabetic wounds demonstrate increased granulation tissue area. The black arrows indicate granulation tissue. *D*: Quantification of granulation tissue. si*Keap1* therapy increases granulation tissue production by \>3.5-fold compared with scramble-treated controls (\**P* \< 0.01). *E*: CD31 immunofluorescence on tissue sections demonstrates increased neovascularization within the wound bed in si*Keap1*-treated wounds. The yellow dotted line demarcates the epidermis (above) and dermis (below). The wound bed is to the right of the yellow dotted line. The open arrowhead indicates low expression; the white arrow indicates high expression. *F*: Quantification of CD31+ cells in granulation tissue (\**P* \< 0.01).](db150453f5){#F5}
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Our study has several important findings. First, we demonstrate a critical Nrf2 signaling defect in chronic hyperglycemia that impairs downstream activation of the antioxidant response program. This defect is manifested on a cellular level through mishandling of intracellular ROS and, on a tissue level, impaired wound regeneration. Moreover, we describe a novel therapeutic strategy using local repression of Keap1, the endogenous Nrf2 inhibitor, to reverse the HG signaling defect, to restore cellular redox homeostasis, and to reestablish regenerative potential in a preclinical model of diabetic tissue injury.

There is growing recognition of the significant role redox homeostasis plays in the pathogenesis of diabetic complications ([@B5]). In particular, the Keap1/Nrf2 signaling pathway regulates the activity of over 50 antioxidant genes ([@B19]). Alterations in this pathway are already implicated in several diabetes-related complications including cardiomyopathy ([@B9],[@B20]), kidney disease ([@B10],[@B12],[@B13]), hepatic steatosis ([@B14],[@B21]), cerebral dementia, and metabolic syndrome ([@B10],[@B21],[@B22]). The common underlying pathologic mechanism involves the loss of redox homeostasis, which in turn contributes to impaired physiologic function on the tissue level. Nrf2-deficient mice are more susceptible to acetaminophen-related liver damage and are characterized by accelerated inflammation and renal injury in diabetic models ([@B23]). Conversely, Keap1 deficiency in mice has a protective role in a cholestatic liver injury model that attenuates liver injury through activation of Nrf2-related detoxifying enzymes and stress genes ([@B24]--[@B26]).

Problems of ROS handling within the heart, liver, and kidneys in the diabetic state have been well documented. However, few studies examine the role of ROS mishandling within cutaneous tissue, despite the overwhelming burden diabetic ulcers pose in the health care system ([@B27]). We sought to understand the role, if any, that Nrf2 signaling has in the pathogenesis of poor healing in the regenerative niche of a diabetic wound.

Our first step was to identify Nrf2 signaling in the context of a diabetic wound. Using an in vitro model of chronic hyperglycemia, we observed that cytoplasmic Nrf2 levels were relatively equivalent to NG conditions, whereas nuclear Nrf2 was detected in smaller amounts when compared with those in normoglycemia. Consistent with this finding, we observed increased amounts of Keap1-bound Nrf2 sequestered in the cytosol. This signaling defect, however, could be forcibly reversed through RNA interference (RNAi) of its repressor, Keap1. This is the first time that the endogenous repressor Keap1 has been targeted to increase Nrf2 signaling in fibroblasts and proposes a new therapeutic strategy in combating ROS mishandling within diabetic wounds.

Prior work has investigated mechanisms affecting Nrf2 localization and activity. Work by Bitar and Al-Mulla ([@B27]) similarly look at Nrf2 signaling differences in diabetic and nondiabetic fibroblasts, demonstrating that Nrf2 degradation occurs at a higher rate in diabetic fibroblasts than in WT ones. They correlate hyperactivity of glycogen synthase kinase 3β to poor nuclear translocation of Nrf2, possibly through phosphorylation of Nrf2 residues. Their use of lithium and thiadiazolidinone to inhibit glycogen synthase kinase 3β partially rescued the observed Nrf2 translocation defect. In addition to the ability of Nrf2 to translocate, other factors may affect its ability to initiate the endogenous antioxidant program. Kawai et al. ([@B28]) report that Nrf2 transcriptional activity may also be influenced by intranuclear acetylation. While our study is the first to target Keap1 to rescue the nuclear translocation defect, there may still be non-Keap1--related factors that explain persistent dysfunction despite rescue of the Nrf2 translocation defect.

We directly observed the immediate downstream effects of the Nrf2 signaling defect through decreased expression of the workhorse antioxidant genes NQO1 and MnSOD. The consequences of their relative inactivation, in conjunction with other redox metabolism--associated genes, correlated with both real-time ROS accumulation, as demonstrated by detection of the ROS stress indicator CM-H~2~DCFDA, and downstream ROS-related DNA adduct accumulation, as shown by 8-OHdG ELISA. Prior work by our lab ([@B29],[@B30]) and others ([@B5],[@B31]--[@B34]) identified such features of ROS accumulation as key characteristics of diabetic pathogenesis, and this study demonstrates that disruption of the Keap1/Nrf2 pathway is a central player in this process.

As a testament to the importance of the Keap1/Nrf2 pathway in the pathogenesis of diabetic complications, our in vivo model demonstrated that diabetic cutaneous regeneration can be enhanced through targeted reduction of Keap1 expression. Consistent with our in vitro results, diabetic wounds treated with topical si*Keap1* demonstrated improved redox homeostasis, as shown by both real-time measurement via L-012 bioluminescence as well as accumulation of 8-OHdG. We found noticeable accumulation of siRNA from the topical therapy, contributing to the improved redox status of diabetic wounds. NQO1, widely recognized as one of the most important antioxidants, is upregulated in the si*Keap1*-treated wound bed. MnSOD, also a crucial antioxidant, however, is not affected by si*Keap1* silencing. The Nrf2 target genes HO-1, GSR, and GSTµ1 are well-known antioxidants ([@B35]--[@B37]), and our results suggest their contribution in the reduction of wound-tissue ROS following *Keap1* silencing. The increases in GSR and GSTµ1 also correlate with the increased GSH-to-GSSG ratio following Keap1 knockdown; these reducing enzymes are key in maintaining the balance between the GSH and oxidized GSSG. The presence of oxidized glutathione leads to reduced GSH-to-GSSG ratios and characterizes oxidative stress ([@B38]). The increased GSH-to-GSSG ratio is a testament to the restored redox balance with *Keap1* knockdown. Gpx1 is also typically involved in antioxidant activity. However, the unremarkable change in Gpx1 expression in our study may reflect a redundant role or imply that Gpx1 is not involved in cutaneous cell redox homeostasis. The slight discrepancy between antioxidant gene expression between in vitro and in vivo studies may be explained by the inability of cell culture to capture a chronic inflammatory status. Nonetheless, the combined effect of Nrf2-downstream antioxidant gene products successfully restored redox handling in both our in vitro and in vivo models.

In conjunction with normalization of redox homeostasis, diabetic wound closure was accelerated and correlated with features of enhanced tissue repair and regeneration, including granulation tissue formation and CD31+ neovascularization. Well-vascularized, healthy granulation is essential to reepithelialization ([@B39],[@B40]). We found increased expression of NGF, FGF1, and FGF2 in the wound bed following *Keap1* silencing as well. Not surprisingly, Peplow and Baxter ([@B41]) found downregulation of these genes in diabetic wounds with delayed healing. Consistent with its role in angiogenesis and tissue repair, FGF1 has been shown to enhance wound healing in an alternative diabetic mouse model NONcNZO10/LtJ, as well ([@B42]). Though there are recognized limitations to the db/db model, here we recapture a similar upregulation of tissue repair--associated growth factors ([@B43]). FGF2 is similarly known to be involved in successful wound healing ([@B44]). Though the molecular and cellular targets of NGF upregulation during wound healing in skin have not been well explored, NGF promotes wound closure in mice and humans ([@B45],[@B46]). Our data show a clear association between the repair of the Keap1/Nrf2 axis in the diabetic model and restoration of the regenerative niche.

In studies of vascularization after tissue injury, Nrf2 expression has been identified as an important promoter in physiological, noninflammatory neovascularization ([@B47]). In the context of neoplasia, however, Nrf2 overexpression is a known mechanism of tumor angiogenesis ([@B48]). Interestingly, HO-1 acts as an anti-inflammatory molecule in addition to its antioxidant role. In this study we found that activated Nrf2 resulted in upregulation of the traditionally proinflammatory cytokines TNF-α and IL-1β in 10-day-old si*Keap1*-treated diabetic wounds. Contrary to expectations of promoting inflammation, these cytokines are known to promote cutaneous wound healing, particularly in the proliferative phases ([@B49]). We show that even in a diabetic skin model, TNF-α and IL-1β reprise their prohealing roles. By contrast, Nrf2-mediated activity downregulated MCP1, a known chemokine for neutrophils and macrophages. Our results agree with the published literature in which forced expression of Nrf2 mitigated the MCP1 induced by ROS stress in human epithelial cells ([@B50],[@B51]). Our data demonstrate that normalizing the Keap1/Nrf2 pathway in diabetic skin reinstates a multitude of healing mechanisms that are characteristic of nondiabetic tissue.

Our cutaneous gene therapy strategy to restore redox homeostasis via *Keap1* suppression is of particular interest. RNAi-based gene therapy, using siRNAs or microRNAs, is a technology that has largely been limited to investigational uses. This therapy is limited by its ability to be effectively targeted to specific areas, requiring high dosages for systemic delivery, with untoward effects ([@B52]). However, the use of topically delivered siRNAs may obviate the traditional barriers to gene therapy because it is limited to local applications, is temporary, and exerts its function extrachromosomally. In this particular case, topical therapy for diabetic wounds would be an ideal application. Since significant *Keap1* knockdown on both the RNA and protein levels occurs within 48 h of transfection, Keap1/Nrf2 turnover lends itself to effective application for an RNAi-based strategy, unlike other targets that may require an extended period of therapy to achieve target protein turnover. Moreover, in prior studies using this technology ([@B18],[@B53]), concerns about off-target effects have been limited to the area of cutaneous application. This is of particular importance because constitutive and unregulated Nrf2 activation has been linked to carcinogenesis and the promotion of malignant neoplastic phenotypes ([@B54]).

There are several implications of this study. First, chronic oxidative stress on fibroblasts impairs Nrf2-mediated maintenance of cellular redox homeostasis, which can be restored through targeted inhibition of *Keap1*. Second, targeted therapeutic strategies to reduce *Keap1* expression can accelerate diabetic tissue regeneration to near-normal levels, improving redox homeostasis and augmenting neovascularization. Finally, a targeted topical siRNA against *Keap1* represents an ideal, rapidly translatable therapeutic strategy to address difficulties in treating cutaneous defects in diabetes.

**Acknowledgments.** The authors would like to thank the Flow Cytometry, Genome Technology Center, Histopathology, and Small Animal Imaging cores at New York University (NYU) Langone Medical Center.

**Funding.** This study was supported in part by grant UL1 TR00038 from the National Center for Advancing Translational Sciences, National Institutes of Health (NIH) (to D.J.C.). The Flow Cytometry, Genome Technology Center, Histopathology, and Small Animal Imaging cores at NYU Langone Medical Center were also partially supported by this grant, as well as the NYU Cancer Center Support Grant, P30CA016087. The study was supported by the NIH National Cancer Institute training grant T32CA160002 to M.A.S.

**Duality of Interest.** No potential conflicts of interest relevant to this article were reported.

**Author Contributions.** M.A.S. researched data and wrote the manuscript. O.D.C. researched data and reviewed the manuscript. Y.C.L. and R.A.S. researched data. T.E., U.A., and L.A. performed experiments, analyzed data, and reviewed the manuscript. J.B.C. reviewed the manuscript. P.B.S. reviewed and edited the manuscript. P.S.R. performed experiments, analyzed data, and wrote, reviewed, and edited the manuscript D.J.C. researched data and reviewed and edited the manuscript. D.J.C. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
